24 January 2025
IXICO plc
("IXICO" or the "Company")
Results of AGM
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:
|
| RESOLUTION | VOTES | % | VOTES | % | VOTES | % ISC VOTED | VOTES |
| 1 | Reports and Accounts | 68,485,623 | 99.95% | 31,468 | 0.05% | 68,517,091 | 73.94 | 400 |
| 2a | Election of Bram Goorden | 68,473,140 | 99.95% | 32,668 | 0.05% | 68,505,808 | 73.93 | 11,683 |
| 2b | Re-election of Grant Nash | 68,474,566 | 99.95% | 36,376 | 0.05% | 68,510,942 | 73.93 | 6,549 |
| 2c | Re-election of Mark Warne
| 68,473,966 | 99.95% | 36,976 | 0.05% | 68,510,942 | 73.93 | 6,549 |
| 2d | Re-election of Dr Dipti Amin | 68,470,760 | 99.95% | 35,048 | 0.05% | 68,505,808 | 73.93 | 11,683 |
| 2e | Re-election of Kate Rogers | 68,475,894 | 99.95% | 35,048 | 0.05% | 68,510,942 | 73.93 | 6,549 |
| 3 | Re-appointment of Moore Kingston Smith Auditors | 68,473,359 | 99.95% | 36,401 | 0.05% | 68,509,760 | 73.93 | 7,731 |
| 4 | Allotment of Securities | 68,475,089 | 99.94% | 41,502 | 0.06% | 68,516,591 | 73.94 | 900 |
| 5 | * Disapply Pre-Emption Provisions | 68,399,849 | 99.83% | 116,742 | 0.17% | 68,516,591 | 73.94 | 900 |
| 6 | * Issue of 'value multiple and exit' share options to Bram Goorden, CEO, and Grant Nash, CFO. | 68,352,128 | 99.76% | 163,273 | 0.24% | 68,515,401 | 73.94 | 2,090 |
| 7 | * To adopt new Articles of Association for the Company | 68,473,361 | 99.94% | 43,830 | 0.06% | 68,517,191 | 73.94 | 300 |
* Special Resolutions
Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation
of the proportion of the votes 'for' and 'against' a resolution.
Further information:
| IXICO plc | +44 (0) 20 3763 7499 | ||
| Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer |
| ||
|
|
| ||
| Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) | +44 (0) 20 7220 0500 | ||
| Giles Balleny / Dan Hodkinson (Corporate Finance) Nigel Birks/Harriet Ward (Corporate Broking) Michael F Johnson / Tamar Cranford Smith (Sales) |
| | |
About IXICO www.IXICO.com
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
